This issue contains a comprehensive review of the most relevant information about targeted therapies, including preclinical studies as well as clinical trials that are ongoing. Attention is given to the main Tirosine Kinase inhibitors, such as anti-EGFR and multitargeted therapies. The newly developed therapies against intracellular pathways responsible for the tumor phenotype (mTOR inhibitors, farnesyltransferase inhibitors, and heat sock protein inhibitors) are also presented. This information is important because these new drugs are being tested in the clinical setting